|Sokal score||Exp 0.01 16 x (age – 43.4) + 0.0345 x (spleen – 7.51) + 0.1880 x [(platelet count/700)2-0.563] + 0.0887 x (blasts -2.10)||Low risk: <0.8|
Intermediate risk: 0.8-1.2
High risk: >1.2
|Hasford score||(0.6666 x age [0 when age <50 years; 1, otherwise] + 0.0420 x spleen + 0.0584 x blasts + 0.0413 x eosinophils + 0.2039 x basophils [0 when basophils <3%; 1, otherwise] + 1.0956 x platelet count [0 when platelets <1500 x I09/L; 1, otherwise]) x 1000||Low risk: ≤780|
Intermediate risk: 781-1480
High risk: >1480
|EUTOS score||(Basophils x 7) + (spleen x 4)||Low risk: ≤87|
High risk: >87
|ELTS score||0.0025 x (age/10)3 + 0.0615 x spleen + 0.1052 x blasts + 0.4104 x (platelet count/1000)-05||Low risk: ≤1.5680|
Intermediate risk: 1.5680-2.2185
High risk: >2.2185
Note: Exp – exponential function; Age is in years; Spleen is in cm below the costal margin; Platelet count is in * I09/L; Blasts, eosinophils and basophils are in percent of peripheral blood.
EUTOS, European Treatment and Outcome Study; ELTS, EUTOS long-term survival.
Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984; 63: 789-99. https://pubmed.ncbi.nlm.nih.gov/6584184/
Thomas M, Irving J, Lennard A, Proctor S, Taylor P. Validation of the Hasford score in a demographic study in chronic granulocytic leukaemia. Journal of Clinical Pathology. 2001;54(6):491-493. doi:10.1136/jcp.54.6.491. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1731441/pdf/v054p00491.pdf
Uz B, Buyukasik Y, Atay H, et al. EUTOS CML prognostic scoring system predicts ELN-based ‘event-free survival’ better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate. Hematology. 2013;18(5):247-52. https://pubmed.ncbi.nlm.nih.gov/23540886/
Yahng SA, Jang EJ, Choi SY, et al. Comparison of Sokal, Hasford and EUTOS scores in terms of long-term treatment outcome according to the risks in each prognostic model: a single center data analyzed in 255 early chronic phase chronic myeloid leukemia patients treated with frontline imatinib mesylate. Blood 2012;120:Abstract 2794.
Marin D, Ibrahim AR, Goldman JM. European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation. J Clin Oncol 2011;29:3944–5. https://ascopubs.org/doi/full/10.1200/jco.2011.37.6962
Yamamoto E, Fujisawa S, Hagihara M, et al. European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. Cancer Sci. 2014;105(1):105-9. https://pubmed.ncbi.nlm.nih.gov/24450386/
Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30(1):48-56. https://pubmed.ncbi.nlm.nih.gov/26416462/
Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study DOI:10.2147/CMAR.S237467
Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, Hoffmann V S, Castagnetti F, Hasford J, Hehlmann R, Simonsson B. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 2015. Article in press.
Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst. 1998; 90: 850-8.
Register on our website right now to have access to more learning materials!
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies (Anthracycline Chemotherapy) – Online Calculator
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies (Anthracycline Chemotherapy)…
The National Institutes of Health Stroke Scale (NIHSS) is a scale designed to assess the…
Charlson Comorbidity Index predicts 10-year survival in patients with multiple comorbidities.
Revised Multiple Myeloma International Staging System (R-ISS) – prognostication tool for myeloma patients based on…
Multiple Myeloma International Staging System (ISS) prognosticates the severity of multiple myeloma based on routinely…